MREO (Mereo BioPharma Group) Tariff Resilience Score: 6/10 (As of Jul. 10, 2026)


MREO Mereo BioPharma Group PLC MREO
19 GF Score
Price $0.34
! 1 Warning Sign
View Full Analysis

What is Mereo BioPharma Group Tariff Resilience Score?

Mereo BioPharma Group MREO +3.33% 19 Tariff Resilience Score is 6 as of Jul. 10, 2026. GuruFocus rates MREO with a GF Score™ of 19/100. The stock has 1 warning sign investors should review. Among 1,369 Biotechnology companies, Mereo BioPharma Group ranks better than 75.97% on this metric.

Mereo BioPharma Group has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Mereo BioPharma Group has Mereo BioPharma's exposure is moderate, with R&D and manufacturing spread globally. The pharmaceutical industry often benefits from tariff exemptions, but supply chain disruptions could affect operations. Historical impacts are limited.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Mereo BioPharma Group might have Average Resilient.

Mereo BioPharma Group  (NAS:MREO) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Mereo BioPharma Group Tariff Resilience Score Related Terms

MREO vs VRTX, REGN, ALNY: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Mereo BioPharma Group's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mereo BioPharma Group Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mereo BioPharma Group's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Mereo BioPharma Group's Tariff Resilience Score falls into.


MREO
19GF Score
Mereo BioPharma Group PLC MREO
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
Mereo BioPharma Group (MREO) has a Tariff Resilience Score of 6 as of Jul. 10, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Mereo BioPharma Group ranks #329 out of 1369 companies in the Biotechnology industry, placing it in the top 24%.
Is Mereo BioPharma Group's Tariff Resilience Score too high?
Mereo BioPharma Group's current Tariff Resilience Score is 6. The Biotechnology industry median Tariff Resilience Score is 4.00. Mereo BioPharma Group's value of 6 is 50% above this industry median. Based on the distribution chart, Mereo BioPharma Group ranks #329 out of 1369 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Mereo BioPharma Group has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Mereo BioPharma Group's Tariff Resilience Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Mereo BioPharma Group ranks #329 out of 1369 companies for Tariff Resilience Score. This places Mereo BioPharma Group in the top 24% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Mereo BioPharma Group's value of 6 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,369 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mereo BioPharma Group's current Tariff Resilience Score of 6 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mereo BioPharma Group's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mereo BioPharma Group stock overvalued right now?
Mereo BioPharma Group (MREO) has a current Tariff Resilience Score of 6. The current Tariff Resilience Score is 6 and 50% above the Biotechnology industry median of 4.00. Mereo BioPharma Group's overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Mereo BioPharma Group (MREO), the current Tariff Resilience Score is 6 as of Jul. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mereo BioPharma Group Business Description

Other Exchanges 0A9G:UKMAH0:Germany
Address One Cavendish Place, 4th Floor, London, GBR, W1G 0QF
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
19GF Score

Get the complete analysis for MREO

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.34
Price